---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045556"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T06:52:22.076196+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q1 net loss $46.6M on $78.8M investment write-down; IST sales up 52%

## Summary
- Net loss of $46.6M ($0.74/share) vs net income of $36.5M in Q1 2024 due to $78.8M unfavorable fair value changes on equity investments.
- Royalty revenue from GSK was $61.3M, largely flat year-over-year.
- U.S. net product sales from IST (GIAPREZA, XACDURO, XERAVA) grew 52% to $26.4M; total net product sales $30.3M.
- Income from operations rose 61% to $41.4M; cash and equivalents $319.1M at quarter end.
- Zoliflodacin NDA on track for H1 2025 filing; ZEVTERA U.S. launch expected mid-2025.

## SEC filing metadata
- accession: 0001104659-25-045556
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/0001104659-25-045556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465925045556/tm2514212d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045556
- JSON: https://secwatch.observer/filing/0001104659-25-045556.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.